IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Bladder Cancer
National Cancer Institute (NCI)protein_peptidePhase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 73/ 100
Competitive context
121 Active assets in the Bladder Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc. | Phase 3 | BBB |
TRASTUZUMAB NKGen Biotech, Inc. | Phase 2 | BB |
Carboplatin G1 Therapeutics, Inc. | Phase 3 | BB |
Cyclophosphamide Beijing Biotech | Phase 3 | BB |
VINBLASTINE University of Southern California | Phase 3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →